Gindi makes first Swiss purchase

Gindi Towers Investments completed its acquisition of an office building in the Swiss city of Morges for NIS 72 million, the company said Sunday.

By AVI KRAWITZ
January 29, 2007 07:30

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Gindi Towers Investments completed its acquisition of an office building in the Swiss city of Morges for NIS 72 million, the company said Sunday. The investment was made through Capital Swissinvest, in which Gindi has a 66.6% stake, marking its first project in Switzerland, expanding outside of its traditional markets in Israel, Hungary and Romania. The building, which houses the local education ministry, has five levels covering 6,315 sq.m. of office space and currently collects NIS 5.6m. in gross rentals a year, Gindi said. Last week, Hungarian Internet publication www.portfolio.hu listed Gindi's East European unit GB Europa among the top 10 real estate companies in Hungary.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS